Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
Ninth Circuit Opens Door to FCA Liability for Alleged 340B OverchargesMarch 19, 2026Fourth Circuit Highlights Tougher Path to Dismissal of FCA Cases Post-SuperValuMarch 18, 2026Fifth Circuit Panel Produces Three Opinions Wrestling with Application of First to File BarMarch 13, 2026Sidley Wins a Trio of Awards at the 2026 Benchmark Litigation US AwardsMarch 12, 2026Strictly Enforcing Rule 9(b), Second Circuit Affirms Dismissal of FCA Claim Based on Allegedly Defective Medical DevicesMarch 4, 2026Court Grants Motion to Dismiss FCA Claim for Failure Adequately to Plead ScienterMarch 3, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory